Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04460170
Other study ID # COFICS201800422
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 1, 2020
Est. completion date February 1, 2022

Study information

Verified date July 2020
Source University Medical Center Groningen
Contact I van der Meulen, PhD
Phone +31503615617
Email i.c.van.der.meulen@pl.hanze.nl
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Since the SARS-CoV-2 infection is relatively new, the long term attributable burden related to COVID19 has not been investigated yet. To date, in patients with COVID-19 and their family members, there is little information on the functional status, cognitive ability, pattern of return to work, and health related quality of life after the ICU admission.

This study aims to describe the psychological wellbeing, physical - and social functioning of COVID-19 ICU survivors and their family members up to 12 months following ICU discharge.


Description:

Study design The COVID-19 Follow up Intensive Care Study (COFICS) is a single center, prospective cohort study performed at a University Medical Center in The Netherlands.

Study population The study population consists of all admitted critically ill COVID-19 patients with a > 48 hours ICU admission at the ICU of a University Medical Center and a family member of the patient. Family members in this study can be partners, other family members, or friends who are identified by the patient as important.

Sample size All consecutive patients admitted to the ICU of the University Hospital for respiratory distress due to COVID-19 between March 19th 2020 and September 30th 2020 will be enrolled. With consent of the patient, family member(s) of participating patients will be enrolled.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date February 1, 2022
Est. primary completion date February 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18 years old

- Ability to speak and write Dutch

- Ability to conduct a telephone call

- Diagnosed with COVID-19 infection (only in patients)

- 48 hours ICU admission (only in patients)

Exclusion Criteria:

- Refuse to participate

- Serious language barrier

- Cognitive impairment

- Severe psychiatric disorder

- Chronic ventilator dependency (only in patients)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (2)

Lead Sponsor Collaborator
University Medical Center Groningen Hanze University of Applied Sciences Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary General Health MOS Short-Form General Health Survey (SF-20). The SF-20 contains 20 items and has six dimensions; physical functioning (min. score 6, max. score 12) rolefunctioning (min. score 2, max. score 4) social functioning (min. score 1, max. score 6) mental health (min. score 5, max. score 30) general health (min. score 5, max. score 25) pain (min. score 1, max score 5) All endscores will be transformed to a 100 points scale where a higher score means better functioning. Except for pain where a higher score means more pain.
The five mental health questions will be excluded from our questionnaire because the questions are comparable with the HADS.
3 months post ICU discharge
Primary General Health MOS Short-Form General Health Survey (SF-20). The SF-20 contains 20 items and has six dimensions; physical functioning (min. score 6, max. score 12) rolefunctioning (min. score 2, max. score 4) social functioning (min. score 1, max. score 6) mental health (min. score 5, max. score 30) general health (min. score 5, max. score 25) pain (min. score 1, max score 5) All endscores will be transformed to a 100 points scale where a higher score means better functioning. Except for pain where a higher score means more pain.
The five mental health questions will be excluded from our questionnaire because the questions are comparable with the HADS.
6 months post ICU discharge
Primary General Health MOS Short-Form General Health Survey (SF-20). The SF-20 contains 20 items and has six dimensions; physical functioning (min. score 6, max. score 12) rolefunctioning (min. score 2, max. score 4) social functioning (min. score 1, max. score 6) mental health (min. score 5, max. score 30) general health (min. score 5, max. score 25) pain (min. score 1, max score 5) All endscores will be transformed to a 100 points scale where a higher score means better functioning. Except for pain where a higher score means more pain.
The five mental health questions will be excluded from our questionnaire because the questions are comparable with the HADS.
12 months post ICU discharge
Primary Anxiety and Depression Hospital Anxiety and Depression Scale (HADS). The HADS contains two subscale of 7 items each. Minimal score is 0, maximal score 21 for each subscale where a higher score means a higher burden. 3 months post ICU discharge
Primary Anxiety and Depression Hospital Anxiety and Depression Scale (HADS). The HADS contains two subscale of 7 items each. Minimal score is 0, maximal score 21 for each subscale where a higher score means a higher burden. 6 months post ICU discharge
Primary Anxiety and Depression Hospital Anxiety and Depression Scale (HADS). The HADS contains two subscale of 7 items each. Minimal score is 0, maximal score 21 for each subscale where a higher score means a higher burden. 12 months post ICU discharge
Primary Long function Spirometry test 6 months post ICU discharge (only in patients)
Primary Long function Spirometry test 12 months post ICU discharge (only in patients)
Primary Frailty Clinical Frailty Scale with a single outcome measure summarizing the overall level of fitness. 3 months post ICU discharge (only in patients)
Primary Frailty Clinical Frailty Scale with a single outcome measure summarizing the overall level of fitness. 6 months post ICU discharge (only in patients)
Primary Frailty Clinical Frailty Scale with a single outcome measure summarizing the overall level of fitness. 12 months post ICU discharge (only in patients)
Primary Family functioning McMaster Family Assessment Device (FAD-GF6+). The FAD-GF6+ contains 6 items (min. score 6, max. score 24) where a higher scores indicate a lower caregiver burden. 6 months post ICU discharge
Primary Family functioning McMaster Family Assessment Device (FAD-GF6+). The FAD-GF6+ contains 6 items (min. score 6, max. score 24) where a higher scores indicate a lower caregiver burden. 12 months post ICU discharge
Primary Effect of an ICU admission on return to work Return to work knowing; possible job loss, change of work activities and worsening employment status 3 months post ICU discharge (only in family members)
Primary Effect of an ICU admission on return to work Return to work knowing; possible job loss, change of work activities and worsening employment status 6 months post ICU discharge
Primary Effect of an ICU admission on return to work Return to work knowing; possible job loss, change of work activities and worsening employment status 12 months post ICU discharge
Secondary age age (years) 24 hours (patient) / 3 months post ICU discharge (family member)
Secondary Gender Gender (male/female) 24 hours (patient) / 3 months post ICU discharge (family member)
Secondary Social status Social status (married/living together/ single) 3 months post ICU discharge
Secondary APACHE IV Acute Physiology And Chronic Health Evaluation (APACHE IV). It is applied within 24 hours of admission of a patient to an intensive care unit (ICU): based on several measurements; higher scores correspond to more severe disease and a higher risk of death 24 hours (only in patients)
Secondary Comorbidity Comorbidity ( free text) 3 months post ICU discharge (only in patients)
Secondary Body mass index Body mass index (kg/m2) 3 months post ICU discharge (only in patients)
Secondary ICU stay ICU stay (days) hospital discharge, an average of 4 weeks (only in patients)
Secondary Mechanical ventilation Mechanical ventilation (days) hospital discharge, an average of 4 weeks (only in patients)
Secondary Delerium Delerium (no / yes --> CAM-ICU / DOS score) hospital discharge, an average of 4 weeks (only in patients)
Secondary Hospital stay Hospital stay (days) hospital discharge, an average of 4 weeks (only in patients)
Secondary Discharge locationn Discharge location (home, other hospital, nursing home, revelidation center) hospital discharge, an average of 4 weeks (only in patients)
Secondary Mortality Mortality (no / yes --> date) 3 months post ICU discharge (only in patients)
Secondary Mortality Mortality (no / yes --> date) 6 months post ICU discharge (only in patients)
Secondary Mortality Mortality (no / yes --> date) 12 months post ICU discharge (only in patients)
Secondary Relationship with the patient Relationship with the patient (Partner, sibling, child, other) 3 months post ICU discharge (only in family members)
Secondary Educational level Educational level (low, middle, high) 3 months post ICU discharge
Secondary Readmission Readmission (no / yes --> free text) 3 months post ICU discharge (only in patients)
Secondary Health care consumption Health care consumption (general practicionar, home care, physiotherapist, lung specialist, psychologist, onther (free text)) 3 months post ICU discharge
Secondary Health care consumption Health care consumption (general practicionar, home care, physiotherapist, lung specialist, psychologist, onther (free text)) 6 months post ICU discharge
Secondary Health care consumption Health care consumption (general practicionar, home care, physiotherapist, lung specialist, psychologist, onther (free text)) 12 months post ICU discharge
Secondary Weight Weight (kg) 3 months post ICU discharge
Secondary Weight Weight (kg) 6 months post ICU discharge
Secondary Weight Weight (kg) 12 months post ICU discharge
Secondary Hypertensive Hypertensive (RR) 3 months post ICU discharge
Secondary Hypertensive Hypertensive (RR) 6 months post ICU discharge
Secondary Hypertensive Hypertensive (RR) 12 months post ICU discharge
Secondary Thrombosis Thrombosis (no / yes --> anticoagulant, DVT or PE) 3 months post ICU discharge
Secondary Thrombosis Thrombosis (no / yes --> anticoagulant, DVT or PE) 6 months post ICU discharge
Secondary Thrombosis Thrombosis (no / yes --> anticoagulant, DVT or PE) 12 months post ICU discharge
Secondary Diabetes Diabetes (no /yes --> current insulin level, metformin/ insulin use) 3 months post ICU discharge
Secondary Diabetes Diabetes (no /yes --> current insulin level, metformin/ insulin use) 6 months post ICU discharge
Secondary Diabetes Diabetes (no /yes --> current insulin level, metformin/ insulin use) 12 months post ICU discharge
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure